Heart rate variability in patients with chronic heart failure and chronic obstructive pulmonary disease: clinical parallels

Abstract

Diseases comorbidity issues are of concern of many researchers, in recent decades, there are attempts to understand the hierarchy of diseases cause-and-effect relationships. Integrative approach to the patient’s condition assessment, whose comorbidity index increases with aging, is of great practical importance, since it allows the practitioner to choose the best drug therapy strategy and to objectively assess the risk of adverse cardiovascular events. Cardiovascular diseases, including those associated with bronchopulmonary system diseases, occupy leading position in mortality rate. One of the most common combinations in clinical practice is a combination of heart failure and chronic obstructive pulmonary disease. Their pathogenetic relationship may be due to common for diseases neurohumoral imbalance. The review presents data on the prevalence and mortality of patients with congestive heart failure and chronic obstructive pulmonary disease, describes the importance of autonomic nervous system dysfunction assessment in cardiovascular and bronchopulmonary diseases combination. Data on the heart rate variability assessment informativeness from the perspective of the clinical characteristics determination relevance and prognosis in patients with congestive heart failure and chronic obstructive pulmonary disease are presented. The main assessed time-domain and spectral parameters are narrated. The results of the heart rate variability parameters study in multicenter clinical trials in patients groups with heart failure and bronchopulmonary obstruction, which define the clinical and prognostic predictors among the heart rate variability parameters, are presented. In general, information on heart rate variability in congestive heart failure in comorbidity with chronic obstructive pulmonary disease is scantily presented in the available literature.

Keywords

comorbidity / congestive heart failure / chronic obstructive pulmonary disease / heart rate variability / time-domain parameters of heart rate / electrocardiogram

References

[1] Авдеев С.Н., Баймаканова Т.Е. ХОБЛ и сердечно-сосудистые заболевания: механизмы ассоциации. Пульмонология. 2008; (1): 5-13.

[2] Беленков Ю.Н., Мареев В.Ю., Скворцов А.А. и др. Эналаприл против карведилола. Сравнительное рандомизированное исследование у больных с хронической сердечной недостаточностью (ЭКСТАЗ). Сердечн. недост. 2001; (2): 84-91.

[3] Волчкова Е.А., Затейщикова А.А., Шаврин И.В. и др. Ассоциация параметров вариабельности ритма сердца с тяжестью бронхиальной обструкции и наличием лёгочной гипертензии у больных хронической обструктивной болезнью лёгких. Кардиология. 2012; (7): 42-48.

[4] Колодяжная О.И. Гендерные особенности вариабельности ритма сердца у пациентов с хронической сердечной недостаточностью зрелого и пожилого возраста. Врач-аспирант. 2013; 57 (2.3): 477-484.

[5] Макаров Л.М. Холтеровское мониторирование ЭКГ. М: Медпрактика-М, 2003; 340 с.

[6] Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (IV пересмотр). Ж. сердечн. недост. 2013; (7): 379-472.

[7] Трубников Г.А., Уклистая Т.А., Андросюк Н.Г. и др. Ремоделирование сердца в свете изменений иммунного статуса у больных хронической обструктивной болезнью лёгких. Клин. мед. 2006; (4): 34-38.

[8] Чучалин А.Г., Айсанов З.Р., Авдеев С.Н. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни лёгких. М. 2013. www.pulmonology.ru/publications/guide.php?clear_cache=Y (дата обращения: 20.05.2015).

[9] Шугушев Х.Х., Гаева А.А. Влияние фуросемида и торасемида на вариабельность сердечного ритма и желудочковые аритмии у больных с хронической сердечной недостаточностью, осложнившей течение ишемической болезни сердца: сравнительное нерандомизированное исследование. Рационал. фармакотерап. в кардиол. 2010; 6 (4): 513-517.

[10] Aronson D., Burger A.J. Effect of beta-blockade on heart rate variability in decompensated heart failure. Int. J. Cardiol. 2001, 79: 31-39. http://dx.doi.org/10.1016/S0167-5273(01)00401-6

[11] Bédard M.E., Marquis K., Poirier P. et al. Reduced heart rate variability in patients with chronic obstructive pulmonary disease independent of anticholinergic or β-agonist medications. COPD. 2010; 7 (6): 391-397. http://dx.doi.org/10.3109/15412555.2010.528083

[12] Borghi-Silva A., Arena R., Castello V. at al. Aerobic exercise training improves autonomic nervous control in patients with COPD. Respir. Med. 2009; 103: 1503-1510. http://dx.doi.org/10.1016/j.rmed.2009.04.015

[13] Boveda M., Galinier M., Pathak A. et al. Prognostic value of heart rate variability in time domain analysis in congestive heart failure. J. Interv. Card. Electophysiol. 2001; 5 (2): 181-187. http://dx.doi.org/10.1023/A:1011485609838

[14] Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370: 741-750. http://dx.doi.org/10.1016/S0140-6736(07)61377-4

[15] Chlabra S.K., Gupta M., Ramaswamy S. et al. Cardiac sympathetic dominance and systemic inflammation in COPD. COPD. 2015; 12 (5): 552-559. http://dx.doi.org/10.3109/15412555.2014.974743

[16] Gunduz H., Talay F., Arinc H. et al. Heart rate variability and heart rate turbulence in patients with chronic obstructive pulmonary disease. Cardiol. J. 2009; 16 (5): 553-559.

[17] Haarmann H., Mohrlang C., Tschiesner U. et al. Inhaled β-agonist does not modify sympathetic activity in patients with COPD. BMC Pulm. Med. 2015; 15 (1): 46. http://dx.doi.org/10.1186/s12890-015-0054-7

[18] Hillebrand S., Gast Karin B. Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression. Europace. 2013; 15: 742-749. http://dx.doi.org/10.1093/europace/eus341

[19] Kudaiberdieva G., Gorenek B., Timuralp B. Heart rate variability as a predictor of sudden cardiac death. Anatol. J. Cardiol. 2007; 7 (1): 68-70.

[20] Lasisi G.T., Adebola A.P., Ogah O.S. et al. Prevalence of ventricular arrhythmias and heart rate variability pattern in chronic heart failure. Niger Postgrad. Med. J. 2012; 19 (3): 157-162.

[21] Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007; 93: 1137-1146. http://dx.doi.org/10.1136/hrt.2003.025270

[22] Musialik-Lydka A., Sredniawa B., Pasyk S. Heart rate variability in heart failure. Cardiol. Pol. 2003; 58 (1): 10-16.

[23] Nolan J., Batin Phillip D., Andrews R. et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom Heart failure evaluation and assessment of risk trial (UK-Heart). Circulation. 1998; 98 (15): 1510-1516. http://dx.doi.org/10.1161/01.CIR.98.15.1510

[24] Paschoal M.A., Petrelluzzi K.F.S., Gonçalves N.V.O. et al. Estudo da variabilidade da frequencia cardiac em pacientes com doenca pulmonary obstructive cronica. Rev. Cienc. Med. 2002; 11 (1): 27-37.

[25] Reis M.S., Arena R., Deus A.P. et al. Deep breathing heart-rate variability is associated with respiratory muscle weakness in patients with chronic obstructive pulmonary disease. Clinics. 2010; 65: 369-375. http://dx.doi.org/10.1590/S1807-59322010000400004

[26] Sidney S., Sorel M., Quesenberry C.P. et al. COPD and incident cardiovascular disease hospitalizations and mortality. Chest. 2005; 128: 2068-2075. http://dx.doi.org/10.1378/chest.128.4.2068

[27] Sin D.D., Wong E., Mayers I. et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability patients with advanced COPD. Chest. 2007; 131 (1): 156-163. http://dx.doi.org/10.1378/chest.06-1423

[28] Van Gestel A.J., Kohler M., Steier J. et al. Cardiac autonomic dysfunction and health-related quality life in patients with chronic obstructive pulmonary disease. Respirology. 2011; 16: 939-946. http://dx.doi.org/10.1111/j.1440-1843.2011.01992.x

[29] Volterrani M., Scalvini S., Mazzuero G. Decreased heart rate variability in patients with chronic obstructive pulmonary disease. Chest. 1994; 106 (5): 1432-1437. http://dx.doi.org/10.1378/chest.106.5.1432

[30] Wu Y.K., Huang C.Y., Yang M.C. at al. Effect of tiotropium on heart rate variability in stable chronic obstructive pulmonary disease patients. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (2): 100-105. http://dx.doi.org/10.1089/jamp.2014.1125

[31] Zamarron C., Lado M.J. et al. Heart rate variability in patients with severe chronic obstructive pulmonary disease in a home care program. Technol. Health Care. 2014; 22 (1): 91-98.

RIGHTS & PERMISSIONS

Gazizianova V.M., Bulashova O.V., Khazova E.V., Nasybullina A.A., Malkova M.I.